Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023

Rhea-AI Summary

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has announced that it will release its first quarter 2023 financial results on May 3, 2023, at 8:00 AM ET. A live conference call will follow to discuss the results and provide a corporate update. Interested parties can access the call through a designated link or via the company’s website. Deciphera focuses on developing innovative medicines for cancer patients, leveraging its proprietary switch-control kinase inhibitor platform. The company’s product, QINLOCK®, is a switch-control inhibitor approved for fourth-line treatment of GIST in several regions, including the U.S. and European Union. For more details, visit deciphera.com.

Positive

• QINLOCK® approved in multiple regions, including the U.S. and European Union, enhancing market reach.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 3, 2023, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed via this link: https://register.vevent.com/register/BI75fb53c225a648b486e50d922b166468

A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005051/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals release its Q1 2023 financial results?

Deciphera Pharmaceuticals will release its Q1 2023 financial results on May 3, 2023.

What time is the conference call for Deciphera Pharmaceuticals' earnings release?

The conference call for Deciphera Pharmaceuticals' earnings release will be held at 8:00 AM ET on May 3, 2023.

Where can I listen to the live webcast of Deciphera Pharmaceuticals' earnings call?

The live webcast of Deciphera Pharmaceuticals' earnings call can be accessed on the company's website in the 'Events and Presentations' section.

What is QINLOCK® and where is it approved?

QINLOCK® is Deciphera's switch-control inhibitor for fourth-line treatment of GIST, approved in regions such as the U.S., Canada, and the European Union.